Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

CUREMAL Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins

Coordinator
Glaxosmithkline Investigacion Y Desarrollo SL, Spain
Runs
1 June 2026 to 30 November 2030
Status
Running
EU funding
€8.4m
Total cost
€22.9m
Partners
11 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101248948

What the project is doing

In the project's own words, from its summary on CORDIS.

CUREMAL project aims to address the urgent need for new malaria treatments due to the increasing resistance to current therapies. Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it causes the majority of malaria-related deaths. The project focuses on developing GSK701, a novel antimalarial compound with a unique mechanism of action, showing no cross-resistance with existing drugs and potential for a single-dose cure.

The partners will conduct two clinical trials to evaluate the safety, efficacy, and pharmacokinetics of GSK701 in combination with pyronaridine. These trials will be carried out in malaria-endemic regions from Gabon, Tanzania, Uganda and Mozambique, targeting vulnerable populations, including children and adolescents. The trials will also involve detailed molecular surveillance to understand the effectiveness of the new treatment and monitor resistance patterns.

Key objectives include assessing the safety and tolerability of various dosing regimens, evaluating the pharmacokinetic/pharmacodynamic relationship, and identifying genetic variants associated with resistance. The project will also focus on building capacity in African research centres for conducting clinical trials and genetic surveillance. The expected outcomes include progressing GSK701 through development stages, enhancing molecular surveillance of antimalarial resistance, and fostering global and intra-African collaborations.

The project aims to contribute to malaria control and elimination efforts, improve treatment adherence with simplified regimens, and support the achievement of the 2030 Sustainable Development Goals related to health. By leveraging multidisciplinary expertise, cutting-edge technology and partners´ in-kind resources, CUREMAL seeks to make a significant impact on public health, providing a robust solution to the growing challenge of antimalarial resistance and advancing towards the ultimate goal of malaria eradication.

Topics

Who is involved

OrganisationCityCountryRole
Glaxosmithkline Investigacion Y Desarrollo SLTres Cantos MadridSpainCoordinator
Mmv Medicines for Malaria VentureCointrinSwitzerlandParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Centre de Recherches Medicales de LambarénéLambarénéGAParticipant
Fundacao ManhicaVila Da Manhica MaputoMZParticipant
The Registered Trustees of the Ifakara Health InstituteDar Es SalaamTZParticipant
Infectious Diseases Research Collaboration Ltd by GuaranteeKampalaUGParticipant
Glaxosmithkline Research & Development LimitedLondonUnited KingdomThird party
Stellenbosch UniversityStellenboschSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI